Other Events ·
On August 31, 2026, Exelixis announced that the U.S. Court of Appeals for the Federal Circuit affirmed a District…
EXELExelixis, Inc.
On August 31, 2026, Exelixis announced that the U.S. Court of Appeals for the Federal Circuit affirmed a District Court judgment upholding the validity of three key patents: Nos. 11,091,439, 11,091,440, and 11,098,015, while dismissing as moot an appeal regarding Patent No. 11,298,349. The ruling delays the earliest effective date for any FDA approval of competitor MSN Laboratories' generic ANDA until January 15, 2030, aligning with the expiration of the affirmed patents. This legal victory preserves Exelixis's market exclusivity and revenue protection for its branded products against generic competition in the oncology sector.